Evidence map›Paper›PMID 42192334›Full record

SynthesisBMC infectious diseases2026

Antimicrobial interventions in multi drug resistance providencia associated infection; a systematic review and meta-analysis of case reports.

Sara Salarian, Maryam Hatam, Mitra Mahmoudi Meymand, Saeed Mohammad Soleymani, Hadi Esmaily

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sara SalarianClinical Research Development Centre, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Maryam HatamClinical Research Development Centre, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mitra Mahmoudi MeymandDepartment of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Niayesh Junction, Vali-e Asr Avenue, Tehran, Iran.ORCID http://orcid.org/0009-0001-7252-9814
Saeed Mohammad SoleymaniClinical Research Development Centre, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0003-1462-3930
Hadi EsmailyClinical Research Development Centre, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Esmaily_hadi@sbmu.ac.ir.ORCID http://orcid.org/0000-0001-6915-6028

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesProvidencia infections are rare but emerging clinical entities with limited published evidence. We performed a pooled descriptive analysis by extracting data from case reports and case series to elucidate the clinical characteristics, outcomes, and potential predictors of adverse events.

methodsA total of 69 cases of Providencia infection were analyzed (mean age: 52.77 ± 21.04 years; 61.19% male). Descriptive statistics were used to summarize patient demographics, clinical characteristics, and infection types. Complete-case data were used for regression analyses specifically, 63 cases for the sepsis outcome, 64 cases for urinary tract infections (UTIs), 62 cases for tracheal aspirates (TAs), and 46 cases for mortality. Logistic regression models with cluster-robust standard errors were applied to account for intra-study dependencies. Variables were selected for multivariable modeling using a backward stepwise approach with a p-value threshold of ≤ 0.3.

resultsThe overall in-hospital mortality was 20.0% (13/69). The predominant infection types were bloodstream infections (sepsis) in 21 cases (30.43%), UTIs in 18 cases (26.09%), and surgical site infections in 17 cases (24.64%). In multivariable regression analysis, the experience of shock during hospitalization emerged as a significant predictor of poor outcome; patients who experienced shock had an adjusted odds ratio of 5.57 (95% confidence interval: 1.26-24.61, p = 0.023) for adverse events. Other factors, such as gender, underlying comorbidities, and various antibiotic administrations (e.g., cephalosporine, beta-lactam, carbapenem), were not independently associated with the outcomes in the final models. Notable exploratory signals: shock→mortality; cephalosporins→UTI; fluoroquinolones→SSI; longer antibiotic duration→lower TA positivity (all imprecise).

conclusionsOur pooled descriptive analysis of Providencia infections reveals an overall mortality rate of 20.0% and identifies shock during hospitalization as an independent predictor of adverse outcomes. Because the evidence is derived from heterogeneous case reports and small case series with substantial missing data, all adjusted estimates are imprecise and should be considered hypothesis‑generating; they must not be used to guide clinical practice without confirmation in prospective studies. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Anti-Bacterial AgentsDrug Resistance, Multiple, BacterialEnterobacteriaceae InfectionsProvidenciaAdultAgedAged, 80 and overCase Reports as TopicFemaleHumansMaleMiddle AgedTreatment OutcomeUrinary Tract InfectionsAnti-Bacterial AgentsAnti-bacterial agentsBacterialDrug resistanceProvidenciaTracheal diseasesUrinary tract infections

Identifiers

PMID42192334
PMCPMC13397606

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.